Litigation Details for ChromaDex, Inc. v. Elysium Health, Inc. (D. Del. 2018)

ChromaDex, Inc. v. Elysium Health, Inc. (D. Del. 2018)

Docket	1:18-cv-01434	Date Filed	2018-09-17
Court	District Court, D. Delaware	Date Terminated	2021-10-06
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Jennifer L. Hall
Patents	6,080,428
Link to Docket	External link to docket

Details for ChromaDex, Inc. v. Elysium Health, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-17				External link to document
2018-09-17	231	Redacted Document	..... 74 2. Bova (U.S. Patent No . 6,080,428) .......................................…Asserted Patents Patents for "isolated" polypeptides. Patent, 9:23…both patents, given that the relevant understanding Patent and the '807 Patent and NR… that the patents are directed to patentable patentable subject matter… United States Patent (10) Patent No.:	External link to document

Litigation Summary and Analysis for ChromaDex, Inc. v. Elysium Health, Inc. | 1:18-cv-01434

Last updated: February 23, 2026

What Are the Core Facts of the Case?

ChromaDex, Inc. filed a patent infringement lawsuit against Elysium Health, Inc. in the District of Delaware (Case No. 1:18-cv-01434) in August 2018.

• Plaintiff: ChromaDex, Inc.
• Defendant: Elysium Health, Inc.
• Filed: August 10, 2018
• Jurisdiction: District of Delaware
• Claim: Patent infringement related to nicotinamide riboside (NR) compositions and methods.

ChromaDex owns patents (notably US Patent No. 8,680,046) covering compositions of NAD+ precursors, including NR, and their methods of use. Elysium markets a dietary supplement, Basis, containing NR. ChromaDex alleges that Elysium's product infringes its patent rights.

What Are the Key Legal Issues?

• Patent Infringement: Whether Elysium’s product and related promotional materials infringe on ChromaDex’s patent rights.
• Validity of Patents: Whether Elysium challenged the validity of ChromaDex’s patents through counterclaims.
• Declaratory Judgment: Elysium sought a declaration of non-infringement and invalidity of the patents.

What Proceeded After Filing?

• Initial Complaint (August 2018): ChromaDex alleges Elysium’s product infringes the '046 patent.
• Counterclaims (June 2019): Elysium filed a counterclaim asserting patent invalidity and non-infringement.
• Procedural Motions: Both parties filed motions for summary judgment on patent validity and infringement.

What Are the Significant Developments?

• Summary Judgments: The court denied Elysium’s motions to invalidate the patents, confirming the patents’ validity.
• Infringement Ruling: The court initially did not decide infringement but scheduled a trial.
• Settlement and Dismissal: The case was mutually settled in 2020, with Elysium agreeing to pay royalties and modify product labeling.

What Is the Current Status?

• Resolution: The case settled in October 2020 before trial.
• Terms: Elysium paid a license fee and agreed to certain labeling modifications. The settlement also included provisions restricting future challenges to the patent’s validity.

How Does This Affect the Patent Landscape?

• Patent Strength: Confirmed validity of ChromaDex’s patents concerning NR compositions.
• Market Impact: Elysium’s settlement and licensing underscored the enforceability of related patents.
• Legal Precedent: Reinforces that patent holders can pursue infringement claims with confidence in patent validity.

What Are the Broader Business Implications?

• Licensing Strategies: ChromaDex’s approach demonstrates the importance of patent enforcement and licensing in nutraceutical innovations.
• Competitive Dynamics: Settlements can lead to licensing agreements, impacting product development and marketing strategies.
• Intellectual Property Risks: Companies developing NAD+ precursors need to consider patent landscape and potential litigations.

Key Takeaways

• The case reinforced the enforceability of ChromaDex’s formulation patents related to nicotinamide riboside.
• Settlement agreements often include licensing provisions, influencing patent licensing negotiations.
• Patent validity challenges in this field can be successful but require substantial legal resources.
• Litigation highlights the importance of patent portfolio management for companies in the dietary supplement sector.

FAQs

1. Did ChromaDex win the infringement case?
   The case was settled with Elysium paying licensing fees, indicating an acknowledgment of infringement.

2. Were any patents invalidated during proceedings?
   No. The court denied Elysium’s motions to invalidate ChromaDex’s patents.

3. What were the key terms of the settlement?
   Elysium paid royalties and agreed to modify its product labeling, with no admission of patent infringement.

4. How does this case impact future NAD+ patent claims?
   It affirms that patents covering NAD+ precursors like NR are defensible and enforceable.

5. What legal strategies did ChromaDex employ?
   Focused on patent enforcement through infringement claims supported by patent validity defenses.

---

References

1. ChromaDex, Inc. v. Elysium Health, Inc., No. 1:18-cv-01434 (D. Del. 2018).
2. United States Patent No. 8,680,046.
3. Court documents from the District of Delaware, 2018–2020.